Fairmount Partners – December News

Fairmount Partners is an independent investment banking firm focused on serving the needs of middle market and emerging growth companies. We provide a complete range of investment banking and capital advisory services for our clients including merger and acquisition advisory, financing advisory, fairness opinions and valuations and strategic corporate development advisory services.

  • Represented ChanTest, a leading provider of specialized laboratory testing services for drug development, and portfolio company of Ampersand Ventures, in their acquisition by life sciences research giant Charles River Laboratories International, Inc. (NYSE: CRL) for a total price of $54 million. This is the second transaction that Fairmount has completed with Ampersand Ventures in the past twelve months, having represented CRI Lifetree, another Ampersand portfolio company, in its sale to PRA International and its PE backer KKR in December of 2013.


  • Acted as the investment banker for the successful sale of Micron Technologies, a leading global provider of particle size engineering technologies to Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. Micron Technologies was previously a portfolio company of Arlington Capital Partners, a Washington, D.C.-based private equity firm. Fairmount Partners represented the prior shareholders and management of Micron Technologies in completing the sale of Micron Technologies to Arlington Capital Partners in March of 2013.

©2020 PACT All Rights Reserved